Antiviral profile of HIV inhibitors in macrophages: Implications for therapy

Current Topics in Medicinal Chemistry

Volumn 4, Issue 9, 2004, Pages 1009-1015

  Perno, C F ^a,b   Balestra, E ^a   Francesconi, M ^c   Abdelahad, D ^c   Calio R ^a   Balzarini, J ^d   Aquaro, S ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c Ospedale di Frascati   (Italy)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACYCLIC NUCLEOSIDE; ADEFOVIR; ANTIVIRUS AGENT; CD4 ANTIGEN; COLONY STIMULATING FACTOR 1; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; M 40401; NEVIRAPINE; NUCLEOSIDE ANALOG; PHOSPHATE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; SUPEROXIDE DISMUTASE; TENOFOVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE;

ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; CELL LINEAGE; DRUG DESIGN; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; NONHUMAN; REVIEW; T LYMPHOCYTE; VIRUS PATHOGENESIS; VIRUS REPLICATION; CD4+ T LYMPHOCYTE; CYTOPATHOGENIC EFFECT; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY; VIROLOGY;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CYTOPATHOGENIC EFFECT, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MACROPHAGES; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

EID: 2942594825     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043388565     Document Type: Review

References (66)

1. Perelson, A.S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A., Saksela, K., Markowitz, M., Ho, D.D. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387, 188-191.
2. Gendelman, H.E., Orenstein, J.M., Martin, M.A., Ferrua, C., Mitra, R., Phipps, T., Wahl, L.A., Lane, H.C., Fauci, A.S., Burke, D.S., Skillman, D.R., Meltzer, M. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J. Exp. Med. 1988, 167, 1428-1441.
3. Orenstein, J.M., Meltzer, M.S., Phipps, T., Gendelman, H.E. Cytoplasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: an ultrastructural study. J. Virol. 1988, 62, 2578-2586.
4. Garaci, E., Caroleo, M.C., Aloe, L., Aquaro, S., Piacentini, M., Costa, N., Amendola, A., Micera, A., Caliò, R., Perno, C.F., Levi-Montalcini, R. Nerve growth factor is an autocrine factor essential for the survival of macrophages infected with HIV. Proc. Natl. Acad. Sci. USA 1999, 96, 14013-14018.
5. Aquaro, S., Bagnarelli, P., Guenci, T., De Luca, A., Clementi, M., Balestra, E., Caliò, R., Perno, C.F. Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. J. Med. Virol. 2002, 68:479-88.
6. Bagnarelli, P., Valenza, A., Menzo, S., Sampaolesi, R., Varaldo, P. E., Butini, L., Montroni, M., Perno, C.F., Aquaro, S., Mathez, D., Leibowitch, J., Balotta, C., Clementi, M. Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo. J. Virol. 1996, 70, 7603-7613.
7. Dimitrov, D.S., Willey, R.L., Sato, H., Chang, L.J., Blumenthal, R., Martin, M.A. Quantitation of human immunodeficiency virus type 1 infection kinetics. J. Virol. 1993 67:2182-90
8. Levy, J.A., Ramachandran, B., Barker, E., Guthrie, J., Elbeik, T. Plasma viral load, CD4+ cell counts, and HIV-1 production by cells. Science 1996, 271:670-671.
9. Coffin, J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-9
10. Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M., Ho, D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
11. Chun, T.W., Carruth, L., Finzi, D., Shen, X., DiGiuseppe, J.A., Taylor, H., Hermankova, M., Chadwick, K., Margolick, J., Quinn, T.C., Kuo, Y.H., Brookmeyer, R., Zeiger, M.A., Barditch-Crovo, P., Siliciano, R.F. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387, 183-188.
12. Swingler, S., Mann, A., Jacque, J., Brichacek, B., Sasseville, V.G., Williams, K., Lackner, A.A., Janoff, E.N., Wang, R., Fisher, D., Stevenson, M. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat. Med. 1999, 5, 997-1103.
13. Palella, F.J. Jr, Delaney, K.M., Moorman, A.C., Loveless, M.O., Fuhrer, J., Statten, G.A., Aschman, D.J., Holberg, S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 1998, 338, 853.
14. Murphy, E.L., Collier, A.C., Kalish, L.A., Assmann, S.F., Para, M.F., Flanigan, T.P., Kumar, P.N., Mintz, L., Wallach, F.R., Nemo, G.J. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann. Intern. Med. 2001, 135, 17-26.
15. De Martino, M., Tovo, P.A., Balducci, M., Galli, L., Gabiano, C., Rezza, G., Pezzotti, P. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 2000, 284, 190-197.
16. Finzi, D., Siliciano, R.F., 19Viral dynamics in HIV-1 infection. Cell 93, 665-671.
17. Chun, T.W., Fauci, S. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc. Natl. Acad. Sci. USA 1999, 96, 10958-10961.
18. Blankson, J.N., Persaud, D., Siliciano, R.F. The challenge of viral reservoirs in hiv-1 infection. Annu. Rev. Med. 2002, 53, 557-593.
19. Chun, T.W., Davey, R.T., Ostrowski, M., Shawn Justement, J., Engel, D., Mullins, J.I., Fauci, A.S. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat. Med. 2000, 6, 757-761.
20. Zhang, L., Chung, C., Hu, B.S., He, T., Guo, Y., Kim, A.J., Skulsky, F., Jin, X., Hurley, A., Ramratnam, B., et al.. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J. Clin. Invest. 2000, 106, 839-845.
21. Lambotte, O., Taoufik, Y., de Goer, M.G., Wallon, C., Goujard, C., Delfraissy, J.F. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 2000, 23, 114-119.
22. Sharkey, M.E., Teo, I., Greenough, T., Sharova, N., Luzuriaga, K., Sullivan, J.L., Bucy, R.P., Kostrikis, L.G., Haase, A., Veryard, C., Davaro, R.E., Cheeseman, S.H., Daly, J.S., Bova, C., Ellison, R.T., Mady, B., Lai, K.K., Moyle, G., Nelson, M., Gazzard, B., Shaunak, S., Stevenson, M. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat. Med. 2000, 6, 76-81.
23. Koenig, S., Gendelman, H.E., Orenstein, J.M., Dal Canto, M.C., Pezeshkpour, G.H., Yungbluth, M., Janotta, F., Aksamit, A., Martin, M.A., Fauci, A.S. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 1986, 233, 1089-1093.
24. Tschachler, E., Groh, V., Popovic, M., Mann, D.L., Konrad, K., Safai, B., Eron, L., diMarzo Veronese, F., Wolff, K., Stingl, G. Epidermal Langerhans cells a target for HTLV-III/LAV infection. J. Invest. Dermatol. 1987, 88, 233-237.
25. McElrath, M.J., Pruett, J.E., Cohn, Z.A. Mononuclear phagocytes of blood and bone marrow: comparative roles as viral reservoirs in human immunodeficiency virus type 1 infections. Proc. Natl. Acad. Sci. USA 1989, 86, 675-679.
26. Meltzer, M.S., Nakamura, M., Hansen, B.D., Turpin, J.A., Kalter, D.C., Gendelman, H.E. Macrophages as susceptible targets for HIV infection, persistent viral reservoirs in tissue, and key immunoregulatory cells that control levels of virus replication and extent of disease. AIDS Res. Hum. Retroviruses 1990, 6, 967-971.
27. Sonza, S., Mutimer, H.P., Oelrichs, R., Jardine, D., Harvey, K., Dunne, A., Purcell, D.F., Birch, C., Crowe, S.M. Monocytes harbour replication-component, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS 2001, 15, 17-22.
28. Innocenti, P., Ottmann, M., Morand, P., Leclercq, P., Seigneurin, J.M. HIV-1 in blood monocytes: frequency of detection of proviral DNA using PCR and comparison with the total CD4 count. AIDS Res. Hum. Retroviruses 1992, 8, 261-268.
29. Williams, K.C., Corey, S., Westmoreland, S.V., Pauley, D., Knight, H., deBakker, C., Alvarez, X., Lackner, A.A. Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. J. Exp. Med. 2001, 193, 905-915.
30. Orenstein, J.M., Fox, C., Wahl, S.M. Macrophages as a source of HIV during opportunistic infections. Science 1997, 276, 1857-1861.
31. Schrager, L.K., D'Souza, M.P. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998, 280, 67-71.
32. Aquaro, S., Perno, C.F., Balestra, E., Balzarini, J., Cenci, A., Francesconi, M., Panti, S., Serra, F., Villani, N., Caliò, R. Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. J. Leukoc. Biol. 1997, 62, 138-143.
33. Aquaro, S., Caliò, R., Balestra, E., Bagnarelli, P., Cenci, A., Bertoli, A., Tavazzi, B., Di Pierro, D., Francesconi, M., Abdelahad, D., Perno, C.F. Clinical implications of HIV dynamics and drug resistance in macrophages. J. Biol. Regul. Homeost. Agents 1998, 12, 23-27.
34. De Clercq, E., Holy, A., Rosemberg, I., Sakuma, T., Balzarini, J., Maudgal, P.C. A novel selective broad-spectrum anti-DNA agent. Nature 1986, 323, 464-467.
35. De Clercq, E., Sacuma, T., Baba, M., Pauwels, R., Balzarini, J., Rasemberg, I., Holy, A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pirimidines. Antiv. Res. 1987, 8, 261-272.
36. Perno, C.F., Balestra, E., Aquaro, S., Panti, S., Cenci, A., Lazzarino, G., Tavazzi, B., Di Pierro, D., Balzarini, J., Caliò, R. Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonlymethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools and cytokines. Mol. Pharm. 1996, 50, 359-366.
37. Naesens, L., Bischofberger, N., Augustijns, P., Annaert, P., Van den Mooter, G., Arimilli, M.N., Kim, C.U., De Clercq, E. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxmethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice. Antimicrob. Agents Chem. 1998, 42, 1568-1573.
38. Balzarini, J., Aquaro, S., Perno, C.F., Witvrouw, M., Holy, A., De Clercq, E. Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxpropyl)-2-6-diaminopurine against human immunodeficiency virus in different human cell systems. Biochem. Bioph. Res. Com. 1996, 219, 337-341.
39. Ahluwalia, G., Cooney, D.A., Mitsuya, H., Fridland, A., Flora K.P., Hao, Z., Dalal, M., Broder, S., Johns, D.G. Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivity. Biochem. Pharmacol. 1987, 36, 3797-3801.
40. Balzarini, J., Kang, G.J., Dalal, M., Herdewijn, P., De Clercq, E., Broder, S., Johns, D.G. The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2′,3′-didehydro-2′,3′-dideoxyribonucleosides: a comparison with their parental 2′,3′-dideoxyribonucleosides. Mol. Pharm. 1987, 32, 162-167.
41. Balzarini, J., Baba, M., Pauwels, R., Herdewijn, P., De Clercq, E., Anti-retrovirus activity of 3′-fluoro- and 3′-azido-substituted pyrimidine 2′,3′ -dideoxynucleoside analogues. Biochem. Pharmacol. 1988, 37, 2847-2856.
42. Balzarini, J., Herdewijn, P., De Clercq, E. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2,′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J. Biol. Chem. 1989, 264, 6127-6133.
43. Johnson, M.A., Fridland, A. Phosphorylation of 2′,3′-dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells. Mol. Pharm. 1989, 36, 291-295.
44. Hao, Z., Cooney, D.A., Farquhar, D., Perno, C.F., Zhang, K., Masood, R., Wilson, Y., Hartman, N.R., Balzarini, J., Johns, D.G. Potent DNA chain termination activity and selective inhibition of human immunodeficiency virus reverse transcriptase by 2′,3′-dideoxyuridine-5′-triphosphate. Mol. Pharm. 1990, 37, 157-163.
45. Haworth, S.J., Christofalo, B., Anderson, R.D., Dunkle, L.M. A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1998, 17, 235-238.
46. Lewis, L.L., Venzon, D., Church, J., Farley, M., Wheeler, S., Keller, A., Rubin, M., Yuen, G., Mueller, B., Sloas, M., Wood, L., Balis, F., Shearer, G.M., Brouwers, P., Goldsmith, J., Pizzo, P.A. Lamivudine in children with human immunodeficiency virus infection: a phase I-II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. J. Infect. Dis. 1996, 174, 16-25.
47. Malorni, W., Lucia, M.B., Rainaldi, G., Cauda, R., Cianfriglia, M., Donelli, G., Ortona, L. Intracellular expression of p170 glycoprotein in peripheral blood mononuclear cell subsets from healthy donors and HIV-infected patients. Haematologica 1998, 83, 13-20.
48. Puech, F., Gosselin, G., Lefebvre, I., Pompon, A., Aubertin, A.M., Kirn, A., Imbach, J.L. Intracellular delivery of nucleoside monophosphates through a reductase-mediated activation process. Antiviral Res. 1993, 22, 155-1
49. Perigaud, C., Aubertin, A.M., Benzaria, S., Pelicano, H., Girardet, J.L., Maury, G., Gosselin, G., Kirn, A., Imbach, J.L. Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA bis(SATE)phosphotriester and 3′-azido-2′,3′-dideoxythymidine. Biochem. Pharmacol. 1994, 48, 11-14.
50. Balzarini, J., Naesens, L., Aquaro, S., Knispel, T., Perno, C.F., De Clercq, E., Meier, C. Intracellular metabolism of cyclosaligen 3′-azido-2′,3′-dideoxythymidine monophosphate, a prodrug of 3′-azido-2′,3′-dideoxythymidine (zidovudine . Mol. Pharmacol. 1999, 56, 1354-1361.
51. Balzarini, J., Aquaro, S., Knispel, T., Ramazzo, C., Bianchi, V., Perno, C.F., De Clercq, E., Meier, C, CycloSaligenyl-2′,3′-didehydro-2′,3′ -dideoxythymidine monophosphate (CycloSal-d4TMP): efficient intracellular delivery of d4TMP. Mol. Pharmacol. 2000, 58, 928-935.
52. Aquaro S., Wedgwood O., Yarnold C., Cahard D., Pathinara R., McGuigan C., Calio' R., De Clercq E., Balzarini J., Perno C.F. Activity of masked 2′-3′-dideoxynucleoside monophosphate derivatives against human immunodeficiency virus in resting macrophages. Antimicrob. Agents Chemother. 2000b, 44, 173-177.
53. De Clercq, E. Reverse transcriptase inhibitors as anti-HIV drugs. In Antivirals against AIDS. Ed by Unger, R.E., Kreuter, J., Rubsamen-Waigman, H., pages 107-150 Mecel Dekker, Inc., New York, 2000.
54. De Clercq, E. Strategies in the design of antiviral drugs. Nat. Rev. 2002, 11, 13-25.
55. Peron, C.F., Aquaro, S., Rosenwirth, B., Balestra, E., Peichl, P., Billich, A., Villani, N., Caliò, R. In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages. J. Leukoc. Biol. 1994, 56, 381-386.
56. Ortiz, G.M., Wellons, M., Brancato, J., Vo, H.T., Zinn, R.L., Clarkson, D.E., Van Loon, K., Bonhoeffer, S., Miralles, G.D., Montefiori, D., Bartlett, J.A., Nixon, D.F. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc. Natl. Acad. Sci. USA 2001, 98, 13288-13293.
57. Lori, F., and Lisziewicz, J. Structured treatment interruptions for the management of HIV infection. JAMA 2001, 286, 2981-2987.
58. Salvemini, D., Wang, Z.Q., Stern, M.K., Currie, M.G., Misko, T.P. Peroxynitrite decomposition catalyst: therapeutics for peroxynitrite-mediated pathology. Proc. Natl. Acad. Sci. USA 1998, 95, 2659-2663.
59. Salvemini, D., Wang, Z.Q., Zweier, J.L., Samouilov, A., Macarthur, H., Misko, T.P., Currie, M.G., Cuzzocrea, S., Sikorski, J.A., Riley, D.P. A nonpeptidyl mimic of superoxide dismutase whith therapeutic activity in rats. Science 1999, 286, 304-306.
60. Cuzzocrea, S., Riley, D.P., Caputi, A.P., Salvemini, D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev. 2001, 53, 135-159.
61. Mollace, V., Nottet, H.S.L.M., Clayette, P., Turco, C., Muscoli, C., Salvemini, D., Perno, C.F. Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants. Trends Neurosci. 2001, 24, 411-416.
62. Mollace, V., Salvemini, D., Riley, D.P., Muscoli, C., Inaccone, M., Granato, T., Masuelli, L., Modesti, A., Rotiroti, D., Nisticò, R., Bertoli, A., Perno, C.F., Aquaro, S. The contribution of oxidative stress in apoptosis of human cultured astroglial cells induced by supernatants of HIV-1 infected macrophages. J. Leukoc. Biol. 2002, 71, 65-
63. Palamara, A.T., Perno, C.F., Aquaro, S., Bue, M.C., Dini, L., Garaci, E. Glutathione inhibits HIV replication by acting at late stages of the virus life cycle. AIDS Res. Hum. Retroviruses 1996, 12, 1537-1541.
64. Garaci, E., Palamara, A.T., Ciriolo, M.R., D'Agostini, C., Abdel-Latif, M.S., Aquaro, S., Lafavia, E., Rotilio, G. Intracellular GSH content and HIV replication in human macrophages. J. Leukoc. Biol. 1997, 62, 54-59.
65. Davis, D.A., Read-Connole, E., Pearson, K., Fales, H.M., Newcomb, F.M., Moskovitz, J., Yarchoan, R. Oxidative modifications of kynostatin-272, a potent human immunodeficiency virus type 1 protease inhibitor: potential mechanism for altered activity in monocytes/macrophages. Antimicrob Agents Chemother 2002 Feb;46(2):402-8
66. Perno, C.F., Fraternale, A., Saccomandi, P., Marcuccilli, F., Caliò, R., Magnani, M., Balestra, E., 20Selective delivery and efficacy of Fludarabine encapsulated in red blood cells to HIV-infected macrophages. 14th International Conference on Antiviral Research. Seattle, Washington,USA, 8-12 Aprile. A56 abstract 61, pag. A56.